These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 30662920)

  • 21. Genetics in Sjögren Syndrome.
    Reksten TR; Lessard CJ; Sivils KL
    Rheum Dis Clin North Am; 2016 Aug; 42(3):435-47. PubMed ID: 27431346
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Colafrancesco S; Ciccacci C; Priori R; Latini A; Picarelli G; Arienzo F; Novelli G; Valesini G; Perricone C; Borgiani P
    J Immunol Res; 2019; 2019():7682827. PubMed ID: 30882006
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An Autoimmune Disease-Associated Risk Variant in the
    Lou L; Bao W; Liu X; Song H; Wang Y; Zhang K; Gao W; Li H; Tu Z; Wang S
    J Clin Microbiol; 2018 Apr; 56(4):. PubMed ID: 29343543
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of the glutathione S-transferase M1 homozygous null genotype with susceptibility to Sjögren's syndrome in Japanese individuals.
    Morinobu A; Kanagawa S; Koshiba M; Sugai S; Kumagai S
    Arthritis Rheum; 1999 Dec; 42(12):2612-5. PubMed ID: 10616008
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Contribution of Genetic Factors to Sjögren's Syndrome and Sjögren's Syndrome Related Lymphomagenesis.
    Nezos A; Mavragani CP
    J Immunol Res; 2015; 2015():754825. PubMed ID: 26550578
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lipoprotein-Associated Phospholipase A2: A Novel Contributor in Sjögren's Syndrome-Related Lymphoma?
    Nezos A; Skarlis C; Psarrou A; Markakis K; Garantziotis P; Papanikolaou A; Gravani F; Voulgarelis M; Tzioufas AG; Koutsilieris M; Moutsopoulos HM; Kotsifaki E; Mavragani CP
    Front Immunol; 2021; 12():683623. PubMed ID: 34220834
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic Variants of the
    Flessa CM; Zampeli E; Evangelopoulos ME; Natsis V; Bodewes ILA; Huijser E; Versnel MA; Moutsopoulos HM; Mavragani CP
    Front Immunol; 2022; 13():836824. PubMed ID: 35371038
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential risk of non-Hodgkin's lymphoma in Italian patients with primary Sjögren's syndrome.
    Valesini G; Priori R; Bavoillot D; Osborn J; Danieli MG; Del Papa N; Gerli R; Pietrogrande M; Sabbadini MG; Silvestris F; Valsecchi L
    J Rheumatol; 1997 Dec; 24(12):2376-80. PubMed ID: 9415645
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rheumatoid Factor and Disease Activity Are Independent Predictors of Lymphoma in Primary Sjögren's Syndrome.
    Nocturne G; Virone A; Ng WF; Le Guern V; Hachulla E; Cornec D; Daien C; Vittecoq O; Bienvenu B; Marcelli C; Wendling D; Amoura Z; Dhote R; Lavigne C; Fior R; Gottenberg JE; Seror R; Mariette X
    Arthritis Rheumatol; 2016 Apr; 68(4):977-85. PubMed ID: 26606524
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MTHFR gene variants and non-MALT lymphoma development in primary Sjogren's syndrome.
    Fragkioudaki S; Nezos A; Souliotis VL; Chatziandreou I; Saetta AA; Drakoulis N; Tzioufas AG; Voulgarelis M; Sfikakis PP; Koutsilieris M; Crow MK; Moutsopoulos HM; Mavragani CP
    Sci Rep; 2017 Aug; 7(1):7354. PubMed ID: 28779180
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of a high-resolution melting method for the screening of TNFAIP3 gene mutations.
    Chang YC; Chang YS; Chang CC; Liu TC; Ko YC; Lee CC; Chang SJ; Chang JG
    Oncol Rep; 2016 May; 35(5):2936-42. PubMed ID: 26986245
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Subclinical atherosclerosis and impaired bone health in patients with primary Sjogren's syndrome: prevalence, clinical and laboratory associations.
    Gravani F; Papadaki I; Antypa E; Nezos A; Masselou K; Ioakeimidis D; Koutsilieris M; Moutsopoulos HM; Mavragani CP
    Arthritis Res Ther; 2015 Apr; 17(1):99. PubMed ID: 25886059
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of interleukin-10 promoter polymorphisms in the clinical expression of primary Sjögren's syndrome.
    Font J; García-Carrasco M; Ramos-Casals M; Aldea AI; Cervera R; Ingelmo M; Vives J; Yagüe J
    Rheumatology (Oxford); 2002 Sep; 41(9):1025-30. PubMed ID: 12209037
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Type I and II interferon signatures in Sjogren's syndrome pathogenesis: Contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis.
    Nezos A; Gravani F; Tassidou A; Kapsogeorgou EK; Voulgarelis M; Koutsilieris M; Crow MK; Mavragani CP
    J Autoimmun; 2015 Sep; 63():47-58. PubMed ID: 26183766
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic variation in tumor necrosis factor and the nuclear factor-kappaB canonical pathway and risk of non-Hodgkin's lymphoma.
    Cerhan JR; Liu-Mares W; Fredericksen ZS; Novak AJ; Cunningham JM; Kay NE; Dogan A; Liebow M; Wang AH; Call TG; Habermann TM; Ansell SM; Slager SL
    Cancer Epidemiol Biomarkers Prev; 2008 Nov; 17(11):3161-9. PubMed ID: 18990758
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjögren's syndrome.
    Tzioufas AG; Boumba DS; Skopouli FN; Moutsopoulos HM
    Arthritis Rheum; 1996 May; 39(5):767-72. PubMed ID: 8639173
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk of non-Hodgkin's lymphoma in primary Sjögren's syndrome: a population-based study.
    Johnsen SJ; Brun JG; Gøransson LG; Småstuen MC; Johannesen TB; Haldorsen K; Harboe E; Jonsson R; Meyer PA; Omdal R
    Arthritis Care Res (Hoboken); 2013 May; 65(5):816-21. PubMed ID: 23139233
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sjögren's syndrome pathological neovascularization is regulated by VEGF-A-stimulated TACE-dependent crosstalk between VEGFR2 and NF-κB.
    Sisto M; Lisi S; Lofrumento DD; D'Amore M; Frassanito MA; Ribatti D
    Genes Immun; 2012 Jul; 13(5):411-20. PubMed ID: 22513453
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation of the NF-κB Pathway and Heterozygous Deletion of TNFAIP3 (A20) Confer Superior Survival in Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type.
    Liu F; Zheng JP; Wang L; Zhao DH; Li MY; Wang YM; Liu Y; Ma J; Zeng NY; Liu HX; Liang R; Guo SP; Wang Z; Yan QG
    Am J Clin Pathol; 2019 Jul; 152(2):243-252. PubMed ID: 31140551
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of transforming growth factor beta1 and tumor necrosis factor alpha polymorphisms with anti-SSB/La antibody secretion in patients with primary Sjögren's syndrome.
    Gottenberg JE; Busson M; Loiseau P; Dourche M; Cohen-Solal J; Lepage V; Charron D; Miceli C; Sibilia J; Mariette X
    Arthritis Rheum; 2004 Feb; 50(2):570-80. PubMed ID: 14872501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.